Blood Stream Infections
PMX-30063 is initially being studied in a multi-national Phase 2 clinical trial to assess its safety and efficacy in treating Acute Bacterial Skin and Skin Structure Infections caused by S. aureus. In the future, we plan to evaluate PMX-30063 for the treatment of other serious infection types, such as blood stream infections (bacteremia and endocarditis) and lung infections (nosocomial pneumonia).